SCLC患者免疫治疗临床获益与肿瘤抗原呈递能力相关
本研究对CheckMate 032试验中286例SCLC患者治疗前肿瘤样本进行RNA测序,评估SCLC亚型及与持续获益相关的表达特征。结果显示抗原呈递机制特征(p=0.000032)及≥1%浸润CD8+ T细胞(HR=0.51,95%CI:0.27-0.95)与纳武利尤单抗治疗患者生存相关,LSD1基因表达与更差生存相关。
要点
- SCLC-A、-N、-P、-Y亚型均与生存无关。
- 抗原呈递机制特征与纳武利尤单抗治疗患者生存相关(p=0.000032)。
- ≥1%浸润CD8+ T细胞与生存相关(HR=0.51,95%CI:0.27-0.95)。
核心结论
- 肿瘤抗原加工与呈递是SCLC患者ICB疗效的关键相关因素。
- 抗原呈递机制在SCLC中常受表观遗传抑制,本研究定义了可能改善ICB临床获益的可靶向机制。
研究设计与样本
- CheckMate 032是一项多中心、开放标签、1/2期试验,评估纳武利尤单抗单药或联合伊匹木单抗。
- 对286例治疗前SCLC肿瘤样本进行综合RNA测序,基于定义的SCLC亚型(SCLC-A、-N、-P、-Y)评估结局。
- 持续获益定义为无进展生存期≥6个月。
- 通过免疫组化进一步探索潜在生物标志物。
主要发现
- SCLC-A、-N、-P、-Y亚型均与生存无关。
- 抗原呈递机制特征与纳武利尤单抗治疗患者生存相关(p=0.000032)。
- 免疫组化显示≥1%浸润CD8+ T细胞与纳武利尤单抗治疗患者生存相关(HR=0.51,95%CI:0.27-0.95)。
- 通路富集分析显示免疫治疗持续获益与抗原加工和呈递相关。
- LSD1基因表达与纳武利尤单抗或纳武利尤单抗联合伊匹木单抗治疗患者更差生存结局相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: A small percentage of patients with SCLC experience durable responses to immune checkpoint blockade (ICB). Defining determinants of immune response may nominate strategies to broaden the efficacy of immunotherapy in patients with SCLC. Prior studies have been limited by small numbers or concomitant chemotherapy administration. METHODS: CheckMate 032, a multicenter, open-label, phase 1/2 trial evaluating nivolumab alone or with ipilimumab was the largest study of ICB alone in patients with SCLC. We performed comprehensive RNA sequencing of 286 pretreatment SCLC tumor samples, assessing outcome on the basis of defined SCLC subtypes (SCLC-A, -N, -P, and -Y), and expression signatures associated with durable benefit, defined as progression-free survival more than or equal to 6 months. Potential biomarkers were further explored by immunohistochemistry. RESULTS: None of the subtypes were associated with survival. Antigen presentation machinery signature (p = 0.000032) and presence of more than or equal to 1% infiltrating CD8+ T cells by immunohistochemistry (hazard ratio = 0.51, 95% confidence interval: 0.27-0.95) both correlated with survival in patients treated with nivolumab. Pathway enrichment analysis revealed the association between durable benefit from immunotherapy and antigen processing and presentation. Analysis of epigenetic determinants of antigen presentation identified LSD1 gene expression as a correlate of worse survival outcomes for patients treated with either nivolumab or the combination of nivolumab and ipilimumab. CONCLUSIONS: Tumor antigen processing and presentation is a key correlate of ICB efficacy in patients with SCLC. As antigen presentation machinery is frequently epigenetically suppressed in SCLC, this study defines a targetable mechanism by which we might improve clinical benefit of ICB for patients with SCLC.
引用
- Rudin CM, Balli D, Lai WV, et al. Clinical Benefit From Immunotherapy in Patients With SCLC Is Associated With Tumor Capacity for Antigen Presentation. J Thorac Oncol. 2023. PMID: 37210008. doi:10.1016/j.jtho.2023.05.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。